{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:09Z","timestamp":1786994409842,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105703","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:45:27Z","timestamp":1718221527000},"page":"105703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-6800","authenticated-orcid":false,"given":"Anu","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Osman","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Massouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruquia","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105703_bib0009","unstructured":"AAN Summary of practice guideline for clinicians practice guideline: disease-modifying therapies for adults with multiple sclerosis starting disease-modifying therapy (DMT) Recommendations."},{"key":"10.1016\/j.msard.2024.105703_bib0102","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom","volume":"8","author":"Abdel-Mannan","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105703_bib0027","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105703_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102640","article-title":"Efficacy and safety of oral prednisolone tapering following intravenous methyl prednisolone in patients with multiple sclerosis relapses: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Bazi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","volume":"81","author":"Benallegue","year":"2024","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0053","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2024.105703_bib0064","unstructured":"Biogen. Tysabri safety consideration. https:\/\/www.tysabri.com\/en_us\/home\/about\/safety-considerations.html?accKey=3."},{"key":"10.1016\/j.msard.2024.105703_bib0082","doi-asserted-by":"crossref","first-page":"E1109","DOI":"10.1212\/WNL.0000000000206750","article-title":"Hematopoietic stem cell transplantation in people with active secondary progressive multiple sclerosis","volume":"100","author":"Boffa","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0104","doi-asserted-by":"crossref","unstructured":"Bove, R. M. & Houtchens, M. K. Pregnancy management in multiple sclerosis and other demyelinating diseases. (2022).","DOI":"10.1212\/CON.0000000000001108"},{"key":"10.1016\/j.msard.2024.105703_bib0100","first-page":"1104","article-title":"Pediatric acquired demyelinating disorders","volume":"28","author":"Brenton","year":"2022","journal-title":"Continuum (Minneap. Minn)"},{"key":"10.1016\/j.msard.2024.105703_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102404","article-title":"Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America","volume":"45","author":"Burt","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006921.pub2","article-title":"Oral versus intravenous steroids for treatment of relapses in multiple sclerosis","author":"Burton","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.105703_bib0111","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.851413","article-title":"Disease-modifying drugs and breastfeeding in multiple sclerosis: a narrative literature review","volume":"13","author":"Capone","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003982.pub2","article-title":"Azathioprine for multiple sclerosis","author":"Casetta","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.105703_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.0000000000005399","article-title":"Complexity of MS management in the current treatment era","volume":"90","author":"Chitnis","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105703_bib0095","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105703_bib0096","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0029","article-title":"Corticosteroids or ACTH for acute exacerbations in multiple sclerosis","volume":"2000","author":"Citterio","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.105703_bib0012","article-title":"The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses","volume":"10","author":"Claflin","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0088","unstructured":"ClinicalTrial.gov. DISCOMS Trial. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03073603 (2023)."},{"key":"10.1016\/j.msard.2024.105703_bib0084","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the american society for blood and marrow transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol. Blood Marrow TransPlant"},{"key":"10.1016\/j.msard.2024.105703_bib0034","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0021","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105703_bib0006","doi-asserted-by":"crossref","unstructured":"Cross, A. & Riley, C. Treatment of multiple sclerosis. (2022).","DOI":"10.1212\/CON.0000000000001170"},{"key":"10.1016\/j.msard.2024.105703_bib0018","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1352458517717808","article-title":"Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations","volume":"24","author":"De Stefano","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105703_bib0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u2018Association of British Neurologists\u2019 guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0107","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/pn-2022-003426","article-title":"Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines","volume":"23","author":"Dobson","year":"2023","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0057","unstructured":"Eckert, S. P., Weinstock-Guttman, B. & Kreiger, S. Point\/counterpoint: food and drug administration multiple sclerosis categorization changes. https:\/\/practicalneurology.com\/articles\/2020-feb\/pointcounterpoint-food-and-drug-administration-multiple-sclerosis-categorization-changes (2020)."},{"key":"10.1016\/j.msard.2024.105703_bib0058","unstructured":"ECTRIMS & EAN. ECTRIMS\/EAN Clinical Guidelines on MS treatment: an update. https:\/\/conferences.medicom-publishers.com\/specialisation\/neurology\/ectrims-2021\/ectrims-ean-clinical-guidelines-on-ms-treatment-an-update\/ (2021)."},{"key":"10.1016\/j.msard.2024.105703_bib0109","unstructured":"EMA. Aubagio Teriflunamide. Summary of product charecteristics (2023)."},{"key":"10.1016\/j.msard.2024.105703_bib0097","unstructured":"European Medicines Agency. Dimethyl fumarate authorisation . https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecfidera (2022)."},{"key":"10.1016\/j.msard.2024.105703_bib0094","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/dmcn.13925","article-title":"Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0042","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0077","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow TransPlant"},{"key":"10.1016\/j.msard.2024.105703_bib0054","unstructured":"FDA. FDA approves new oral treatment for multiple sclerosis. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-treatment-multiple-sclerosis (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102627","article-title":"Cyclophosphamide in treatment of tumefactive multiple sclerosis","volume":"47","author":"Fereidan-Esfahani","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0066","article-title":"Rituximab for people with multiple sclerosis","volume":"11","author":"Filippini","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.105703_bib0048","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis","volume":"131","author":"Fisniku","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105703_bib0108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4049\/immunohorizons.1700057","article-title":"The impact of IgG transplacental transfer on early life immunity","volume":"2","author":"Fouda","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.msard.2024.105703_bib0073","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1007\/s10072-021-05052-1","article-title":"Cyclophosphamide treatment in active multiple sclerosis","volume":"42","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.msard.2024.105703_bib0005","unstructured":"GDP per capita (current US$) - United Kingdom, United States, European Union, United Arab Emirates | Data. https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=GB-US-EU-AE&most_recent_value_desc=true."},{"key":"10.1016\/j.msard.2024.105703_bib0112","doi-asserted-by":"crossref","DOI":"10.3390\/ph16050770","article-title":"Monoclonal antibodies in pregnancy and breastfeeding in patients with multiple sclerosis: a review and an updated clinical guide","volume":"16","author":"Gklinos","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.msard.2024.105703_bib0072","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.63.10.noc60076","article-title":"High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis","volume":"63","author":"Gladstone","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0044","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/jnnp.2008.166421","article-title":"Prior suggestive symptoms in one-third of patients consulting for a \u2018first\u2019 demyelinating event","volume":"82","author":"Gout","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105703_bib0069","unstructured":"Gunhild Hagen, Ulrikke Lund, Atle Fretheim & Vida Hamidi. Disease modifying treatments for relapsing remitting multiple sclerosis. a health economic evaluation. https:\/\/www.fhi.no\/en\/publ\/2019\/Disease-modifying-treatments-for-relapsing-remitting-multiple-sclerosis\/ (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0050","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105703_bib0065","doi-asserted-by":"crossref","unstructured":"Hauser, S. L. et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. www.nejm.org (2008).","DOI":"10.1056\/NEJMoa0706383"},{"key":"10.1016\/j.msard.2024.105703_bib0060","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0056","first-page":"S43","article-title":"The future of progressive multiple sclerosis therapies","volume":"37","author":"Hollen","year":"2020","journal-title":"Fed. Pract."},{"key":"10.1016\/j.msard.2024.105703_bib0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00207454.2011.565893","article-title":"Prevalence of multiple sclerosis in Dubai, United Arab Emirates","volume":"121","author":"Inshasi","year":"2011","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2024.105703_bib0092","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0883073818759103","article-title":"Pediatric multiple sclerosis in the United Arab Emirates: characteristics from a multicenter study and global comparison","volume":"33","author":"Ismail","year":"2018","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-022-00421-0","article-title":"Multiple sclerosis in pregnancy: a commentary on disease modification and symptomatic drug therapies","volume":"12","author":"Iyer","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2024.105703_bib0083","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ana.25842","article-title":"Complications from \u2018stem cell tourism\u2019 in neurology","volume":"88","author":"Julian","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0051","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105703_bib0022","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2023.101054","article-title":"Pediatric multiple sclerosis","volume":"46","author":"Kornbluh","year":"2023","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0090","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2024.105703_bib0099","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0071","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002819.pub2","article-title":"Cyclophosphamide for multiple sclerosis","author":"La Mantia","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.105703_bib0038","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105703_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad073","article-title":"The radiologically isolated syndrome: revised diagnostic criteria","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105703_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.25799","article-title":"Radiologically isolated syndrome: 10-year risk estimate of a clinical event","volume":"88","author":"Lebrun-Frenay","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0031","article-title":"Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: a meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2024.105703_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2024-333597","article-title":"Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis","author":"Maarouf","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105703_bib0075","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0b013e3181a8164c","article-title":"Cyclophosphamide therapy in pediatric multiple sclerosis","volume":"72","author":"Makhani","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0087","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000960","article-title":"Defining benign\/burnt-out MS and discontinuing disease-modifying therapies","volume":"8","author":"McFaul","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105703_bib0086","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society","volume":"78","author":"Miller","year":"2021","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pathog.2016.04.001","article-title":"Multiple sclerosis is prominent in the Gulf states: review","volume":"3","author":"Mohammed","year":"2016","journal-title":"Pathogenesis"},{"key":"10.1016\/j.msard.2024.105703_bib0059","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105703_bib0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0030","doi-asserted-by":"crossref","unstructured":"Morrow, S. A. Stoian, C. A, Dmitrovic, J, Chan, S C & Metz, L. M. Brief communications the bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. http:\/\/mscare.com. (2004).","DOI":"10.1212\/01.WNL.0000138572.82125.F5"},{"key":"10.1016\/j.msard.2024.105703_bib0079","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0014","unstructured":"National MS Society USA. Disease-modifying therapies for MS. Treating MS https:\/\/www.nationalmssociety.org\/Treating-MS\/Medications (2023)."},{"key":"10.1016\/j.msard.2024.105703_bib0015","unstructured":"NHS England. Flow chart NHS England MS disease modifying treatment algorithm. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2019\/03\/Treatment-Algorithm-for-FlowChartMultiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0025","unstructured":"NHS England. Treatment algorithm for multiple sclerosis disease-modifying therapies NHS England Reference: 170079ALG treatment algorithm for multiple sclerosis disease-modifying therapies contents. (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0024","unstructured":"NICE Technology appraisal guidance [TA616]. Cladribine for treating relapsing\u2013remitting multiple sclerosis. https:\/\/www.nice.org.uk\/guidance\/ta616\/chapter\/1-Recommendations (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0019","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0046","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0063","article-title":"Identification and management of subclinical disease activity in early multiple sclerosis: a review","author":"Ontaneda","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/13524585231168043","article-title":"ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs","author":"Otero-Romero","year":"2023","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2024.105703_bib0032","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1468-1331.2008.02146.x","article-title":"Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis","volume":"15","author":"Perumal","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0011","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0026","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105703_bib0052","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105703_bib0067","doi-asserted-by":"crossref","unstructured":"Salzer, J. et al. Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy. (2016).","DOI":"10.1212\/WNL.0000000000003331"},{"key":"10.1016\/j.msard.2024.105703_bib0110","unstructured":"Sanofi. Accelerated elimination procedure for Teriflunamide. https:\/\/www.aubagiohcp.com\/prescribing-aubagio (2023)."},{"key":"10.1016\/j.msard.2024.105703_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2016.07.005","article-title":"How global MS prevalence is changing: a retrospective chart review in the United Arab Emirates","volume":"9","author":"Schiess","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow TransPlant"},{"key":"10.1016\/j.msard.2024.105703_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review\u2730","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1352458516645670","article-title":"NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105703_bib0081","doi-asserted-by":"crossref","unstructured":"Sormani, M. P. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis a meta-analysis. (2017).","DOI":"10.1212\/WNL.0000000000003987"},{"key":"10.1016\/j.msard.2024.105703_bib0068","unstructured":"Stoltenberg, C. & Atle, F. Title disease-modifying treatments for relapsing remitting multiple sclero. (2019)."},{"key":"10.1016\/j.msard.2024.105703_bib0098","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of dimethyl fumarate vs interferon \u03b2-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial","volume":"5","author":"Vermersch","year":"2022","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.msard.2024.105703_bib0037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105703_bib0023","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105703_bib0036","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.39.9.1143","article-title":"Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"39","author":"Weiner","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105703_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jca.1010","article-title":"Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system","volume":"16","author":"Weinshenker","year":"2001","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.msard.2024.105703_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0113","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/bfm.2014.0107","article-title":"Lactation and the use of biologic immunosuppressive medications","volume":"9","author":"Witzel","year":"2014","journal-title":"Breastfeeding Med."},{"key":"10.1016\/j.msard.2024.105703_bib0039","unstructured":"World Health Organization. WHO model list of essential medicines - 23rd list, 2023. 6\u20136 https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02 (2023)."},{"key":"10.1016\/j.msard.2024.105703_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9084759","article-title":"Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study","volume":"2018","author":"Yamout","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.msard.2024.105703_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105703_bib0091","series-title":"Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis","author":"Yan","year":"2020"},{"key":"10.1016\/j.msard.2024.105703_bib0041","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T23:21:14Z","timestamp":1723591274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":109,"alternative-id":["S2211034824002803"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105703","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105703"}}